Iborra Marisa, Beltrán Belén, Nos Pilar
Gastroenterology Department, Department of Digestive Disease, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), La Fe University and Polytechnic Hospital, Av. Fernando Abril Martorell, 106, Valencia 46026, Spain.
Gastroenterology Department, Department of Digestive Disease, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), La Fe University and Polytechnic Hospital, Av. Fernando Abril Martorell, 106, Valencia 46026, Spain.
Gastrointest Endosc Clin N Am. 2016 Oct;26(4):641-56. doi: 10.1016/j.giec.2016.06.005. Epub 2016 Aug 9.
Biomarkers have gained increasing attention for the diagnosis and follow-up of inflammatory bowel disease (IBD). Endoscopy remains the gold standard for assessing disease activity. Biomarkers are rapid, inexpensive, and noninvasive, and can be used in different stages of the disease with high sensitivity and specificity. Calprotectin and tests for C-reactive protein are used to assess the disease activity, predict relapse, and monitor treatment response. New noninvasive tests are being studied. This review discusses current evidence for these surrogate markers, their potential clinical applications, and limitations in disease management. We highlight recent advances in IBD biomarkers and future uses.
生物标志物在炎症性肠病（IBD）的诊断和随访中受到越来越多的关注。内镜检查仍然是评估疾病活动度的金标准。生物标志物快速、廉价且非侵入性，可在疾病的不同阶段以高灵敏度和特异性使用。钙卫蛋白和C反应蛋白检测用于评估疾病活动度、预测复发和监测治疗反应。新的非侵入性检测正在研究中。本综述讨论了这些替代标志物的现有证据、它们潜在的临床应用以及在疾病管理中的局限性。我们重点介绍了IBD生物标志物的最新进展和未来用途。
